// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Categorising sub-massive pulmonary thromboembolism: no isolated role for shock index or its modified form

Saleel Punnilath Abdulsamad - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Thoracic CT features of patients with BMPR2 mutation: preliminary analysis from the UK National Cohort Study of Idiopathic and Heritable PAH

Marcella Cogliano - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Diagnostic accuracy of right ventricular trabecular mass measurements as measured on cardiac MRI in suspected pulmonary hypertension

Alistair Macdonald - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Pulmonary arterial hypertension

N/A

Diagnostic and prognostic value of a diagnostic CT regression model in suspected pulmonary hypertension

Andy Swift - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Pulmonary arterial hypertension

N/A

Using Step Count to Enhance Daily Physical Activity in PH, a pilot-study (STEP in PH)

Beatrice Vigo - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Pulmonary arterial hypertension

N/A

Cell freehaemoglobin and pulmonary artery endothelial cell dysfunction

Quezia Toe - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Vasodilation dysfunction

N/A

MiR-1-5p targets TGF-ßR1 and is suppressed in the hypertrophying hearts of rats with pulmonary arterial hypertension

Martin Connolly - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Pulmonary arterial hypertension

Monocrotaline

PULSAR: A phase 2, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of sotatercept (ACE-011) when added to standard of care (SOC) for treatment of pulmonary arterial hypertension (PAH)

David Badesch - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Pulmonary arterial hypertension

Sotatercept

A retrospective review of computed tomography (CT) findings in Eisenmenger Syndrome and their prognostic implications

Sobitha Sathianandan - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Complex calcified coronary artery lesions

N/A

Safety, tolerability, pharmacokinetics and pharmacodynamics after repeated once or twice daily RVT-1201, a TPH inhibitor for treatment of PAH

Stephen Wring - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Impact of ILD severity and subtype on outcomes in CTD-associated PAH

Robert Hastings - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Targeting of mitochondrial superoxide in chronic hypoxia-induced pulmonary hypertension

Nasim Alebrahimdehkordi - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Pulmonary arterial hypertension

N/A

Pulmonary vascular cell mitochondrial dysfunction in response to hepcidin

Theo Issitt - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Pulmonary arterial hypertension

N/A

Late Breaking Abstract - The effects of BMPRII loss on endothelial shear adaptation in the pulmonary vascular endothelium

Abdul Mahomed - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Risk stratification of pulmonary arterial hypertension (PAH) associated with adult congenital heart disease (ACHD)

Sheila Ramjug - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Pulmonary arterial hypertension

N/A

A prospective study comparing the repeatability and sensitivity to change of non-invasive endpoints in pulmonary arterial hypertension: the RESPIRE study

David Kiely - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Pulmonary arterial hypertension

N/A

KCa3.1 ion channel is expressed by component cells of lymphangioleiomyomatosis (LAM) nodules

Shams-un-nisa Naveed - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Lymphangioleiomyomatosis

N/A

BMS-986278, a lysophosphatidic acid 1 (LPA1) receptor antagonist, in healthy participants: A single/multiple ascending dose (SAD/MAD) phase 1 study

Giridhar Tirucherai - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Assessment of Treatment Response in Granulomatous Lymphocytic Interstitial Lung Disease (GLILD)

Georgia Gkrepi - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Interstitial lung disease

Prednisolone

Outcome of weekly Consultant-Led Multidisciplinary Meetings in Pulmonary Rehabilitation

Maria Koulopoulou - European Respiratory Society (ERS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved